Summary

  • Iridium shareholders are not being offered a fixed US$54 cash-equivalent amount. Each eligible share receives US$27 in cash and Rocket Lab shares determined by a three-zone exchange ratio.
  • Inside a US$67.50–US$112.50 Rocket Lab measurement-price band, the ratio floats to keep the stock leg near US$27. Below it the ratio stops at 0.4000; above it the ratio stops at 0.2400. Consideration then falls or rises with Rocket Lab’s price.
  • The ratio uses a ten-trading-day Nasdaq VWAP ending on the second full trading day before the first effective time. Rocket Lab shares can move after that window, so even the collar’s centre does not guarantee US$54 of market value when the shares arrive.

A vote on a mechanism, not a number

The first page of the Iridium proxy gives shareholders two facts that do not sit comfortably together. The proposed sale to Rocket Lab is described at a notional US$54 per Iridium share. The document then says the value will fluctuate with Rocket Lab common stock until the transaction is complete.

Both are accurate. They describe different layers of the contract.

US$27 of the consideration is cash. The other US$27 is a target value delivered in Rocket Lab shares. A collar changes the number of shares in order to stabilise that stock leg over a defined range. Outside the range, the adjustment stops. The buyer no longer issues more shares to compensate for a lower price, or fewer shares to retain all of a higher price.

Iridium filed the definitive proxy statement on 26 August. The virtual special meeting is scheduled for 24 September at 8:30 a.m. Eastern Time, with 21 August as the record date. Adoption requires the affirmative vote of holders of a majority of all outstanding Iridium common shares entitled to vote, not merely a majority of those that turn up.

That vote does not close the transaction. It approves a machine whose final output will be calculated near a closing currently expected in mid-2027. Between the vote and delivery sit a Rocket Lab trading range, a financing decision and several regulatory approvals. The useful question is therefore not whether US$54 sounds attractive. It is which variable controls each part of that figure.

The centre is flat; the tails are not

The definitive proxy sets out three zones. Let P denote the contractual Rocket Lab Stock Price.

If P is at or below US$67.50, each Iridium share receives 0.4000 Rocket Lab share. If P is above US$67.50 but below US$112.50, the ratio is US$27 divided by P, rounded to four decimals. If P is at or above US$112.50, the ratio is 0.2400.

The two boundaries reveal the design. At US$67.50, 0.4000 share is worth US$27. At US$112.50, 0.2400 share is also worth US$27. Between those prices, the number of shares moves inversely with P: a lower price produces more shares and a higher price produces fewer. Add the fixed US$27 cash leg, and the contractual value at the measurement price stays close to US$54, allowing for four-decimal rounding.

Below the lower boundary, the maximum share count has been reached. At an illustrative US$60 measurement price, 0.4000 share is worth US$24, making combined consideration US$51. At US$50, it is US$20 of stock and US$47 in total. These are applications of the formula, not predictions.

Above the upper boundary, the minimum share count has been reached. At an illustrative US$125 measurement price, 0.2400 share is worth US$30, taking combined consideration to US$57. At US$150, the stock leg is US$36 and the total US$63.

This is not simply buyer protection. The collar allocates two different risks. Inside the band, Rocket Lab absorbs dilution risk because a lower share price requires more shares, while Iridium holders receive a relatively stable stock value. Below US$67.50, Iridium holders absorb further Rocket Lab downside because the share count cannot rise. Above US$112.50, they retain further upside because the share count cannot fall.

The US$54 announcement value is therefore the flat middle of a piecewise payoff. Calling it a fixed bid removes the feature that determines who bears the next dollar of Rocket Lab volatility.

Ten days set the ratio; two days remain exposed

The contract does not use Rocket Lab’s price on announcement day, voting day or an analyst’s chosen date. It defines the Rocket Lab Stock Price as the Nasdaq volume-weighted average over ten consecutive trading days ending on and including the second full trading day before the first effective time. Bloomberg is the named source, with another mutually selected authoritative source available if necessary.

That definition reduces the influence of a single volatile close. It also creates a clock. Shareholders will approve the deal months before the measurement window exists. The final ratio will become calculable only on the second full trading day before the first effective time.

The window does not remove all price risk. Once the ten-day VWAP has fixed the ratio, Rocket Lab shares continue trading. Their spot value at the effective time, and after holders can trade them, can differ from the VWAP used to determine how many shares they receive. The proxy explicitly warns that holders will not know the actual ratio or be able to calculate the market value of the stock consideration when they vote.

The document uses 18 August as an illustration. At Rocket Lab’s closing price on that date, the ratio would have been 0.3411. That number is not a deal term and should not be carried into a closing model. It demonstrates that the reference price sat inside the collar on the proxy’s practicable date; the real ratio depends on a future ten-day average.

At that illustrative ratio, existing Rocket Lab holders were estimated to own about 95% of the combined voting power and former Iridium holders about 5%. The final percentages depend on the ratio and both companies’ capitalisation at closing. A floating share count means the collar is also a dilution allocator.

One antitrust clock has stopped; the licence clocks have not

The HSR waiting period expired at 11:59 p.m. Eastern Time on 12 August. That removes a specified waiting-period condition. It does not amount to a completed regulatory clearance package, and it does not prevent later antitrust action.

Iridium’s network depends on licences and authorisations that cannot be transferred by a press release. The merger remains subject to FCC approval for the transfer of control of Iridium’s space-station, gateway earth-station, blanket earth-station, experimental and international Section 214 authorisations. The FCC can refer the transaction to Team Telecom. Satellite and communications laws, the National Industrial Security Program, foreign investment rules and approvals tied to non-U.S. telecom licences add other decision-makers.

The proxy names required or potentially required reviews across multiple jurisdictions, including Australia, New Zealand and the United Kingdom for foreign investment, and several countries for telecom licences. The parties expect completion in mid-2027, but the initial contractual end date is 28 June 2027. If specified regulatory conditions are all that remain, it can extend automatically first to 28 September and then to 28 December.

Those dates turn regulation into an economic variable. A longer pending period extends uncertainty over the share ratio, permanent financing and Iridium’s freedom to make large capital decisions. It also moves the VWAP window, so a delay can change the consideration even when the legal terms do not change.

Rocket Lab has consent rights before it has ownership

The pending period is not neutral. Subject to stated exceptions, Iridium must use commercially reasonable efforts to operate in the ordinary course and preserve its organisation, material permits, satellites, constellation and commercial relationships.

Without Rocket Lab’s consent or another contractual exception, Iridium is restricted from buying businesses, opening a new material line, disposing of assets, exceeding disclosed capital budgets, making material investments, incurring more than US$5mn of new borrowed debt outside permitted cases, entering specified material contracts or materially changing satellites and telecom permits. Rocket Lab accepts a narrower set of interim restrictions of its own.

These provisions do not make Rocket Lab Iridium’s owner before closing. They give the buyer a consent surface designed to preserve what it agreed to purchase. The distinction matters for both governance and accountability. Iridium’s board and management still operate the company, regulators still control licences and shareholders still control adoption. Yet some decisions that would normally belong to management now require the counterparty’s permission.

The lock is most relevant where a satellite operator cannot pause time. Constellation maintenance, spectrum authorisations, customer commitments and next-generation investment continue while the acquisition waits. A covenant can preserve an asset from an unexpected transaction; it can also narrow the operator’s response to a new opportunity. The proxy’s exceptions and confidential disclosure schedules may permit pre-agreed actions, so the public list should not be read as proof that a specific project is blocked.

The break fee is one-way, but not universal

Iridium can owe Rocket Lab US$223.62mn if it terminates for a superior proposal or in specified board-recommendation and no-shop circumstances. A tail provision can also apply when an acquisition proposal precedes certain terminations and a qualifying alternative deal follows within twelve months. The proxy says the fee represents about 3.75% of implied equity value on the parties’ 26 June calculation.

The agreement does not impose that fee merely because required regulatory approvals fail. It also contains no reverse termination fee payable by Rocket Lab to Iridium and no contractual reimbursement of either side’s expenses on termination.

That asymmetry should be described precisely. The fee makes a competing bid more expensive to pursue and gives Rocket Lab protection against specified seller actions. It is not a general insurance policy for the buyer, and its absence on the reverse side does not prove that Rocket Lab can walk away without satisfying the agreement’s termination conditions.

Financing adds another asymmetry. Rocket Lab has commitments for a US$3.6bn, 364-day senior secured bridge facility. It expects to fund the cash leg with cash on hand and debt and/or equity financing, then reduce or replace the bridge through permanent financing. The mix and terms were not determined as of 26 August.

If Rocket Lab issues equity, existing owners absorb dilution beyond the shares paid to Iridium holders. If it relies more heavily on debt, the combined company carries more interest and refinancing exposure while funding Rocket Lab’s Neutron programme and the eventual replacement of Iridium’s constellation. The collar decides how many acquisition shares are issued. The financing plan decides how the fixed cash half is carried.

US$54 is useful shorthand for the transaction’s centre. It is poor shorthand for the risks around it. The definitive proxy turns the headline into four things to monitor: a piecewise stock payoff, a near-closing measurement window, a regulatory calendar and a financing choice.

Sources